Development and application of polysaccharide conjugate vaccine carrier protein
10.3760/cma.j.cn112150-20250326-00245
- VernacularTitle:多糖结合疫苗载体蛋白的研发与应用
- Author:
Jingxin LI
1
;
Xiao MA
;
Ang LIN
;
Hongxing PAN
;
Bo HAO
;
Juan SHAO
;
Yuezhu LI
;
Yangting XU
;
Zhujun SHAO
;
Aiqiang XU
Author Information
1. 江苏省医学创新中心 国家卫生健康委员会肠道病原重点实验室 江苏省疾病预防控制中心（江苏省预防医学科学院），南京 210009
- Publication Type:Journal Article
- Keywords:
Carrier protein;
Immunogenicity;
Polysaccharide conjugate vaccine;
Vaccine research and development
- From:
Chinese Journal of Preventive Medicine
2025;59(7):1131-1140
- CountryChina
- Language:Chinese
-
Abstract:
The development of polysaccharide conjugate vaccines, which convert polysaccharide antigens into T-cell-dependent immunogens through covalent conjugation with protein carriers, represents a critical strategy for enhancing immune protection in infants and young children. Globally licensed conjugate vaccines currently employ carrier proteins including Tetanus Toxoid, Diphtheria Toxoid, and Cross-Reacting Material 197. Recent advances have focused on three key areas: novel carrier protein discovery, optimized conjugation strategies, and evaluation of immune interference during co-administration of multivalent formulations. These efforts aim to achieve broader serotype coverage, prolonged protective efficacy, and simplified immunization schedules. This review synthesizes recent progress in carrier protein development, encompassing vaccine design principles, manufacturing processes, safety profiles, and epidemiological effectiveness. Furthermore, it critically examines current selection criteria for carrier proteins, their clinical applications, and persistent challenges, providing strategic insights to inform future conjugate vaccine development and immunization policy optimization in China.
